Dr. Zhang Juan


Dr. Zhang Juan

Position Postdoctoral Fellow
Office G09, Run Run Shaw Science Building, The Chinese University of Hong Kong, Hong Kong
Tel. (852) 3943 1231
Fax. (852) 3942 0972
Email This email address is being protected from spambots. You need JavaScript enabled to view it.

Resume (Education and Working Experience)


  1. 2011 B.S.(Pharmacy), Anhui University of Traditional Chinese Medicine
  2. 2015 M.A.(Chinese Medicine), Yunnan University of Traditional Chinese Medicine
  3. 2019 Ph.D.(Chinese Medicine), Shanghai University of Traditional Chinese Medicine

Work Experience:

  1. 2020-Now Postdoctoral Fellow, School of Chinese Medicine, CUHK
  2. 2019-2020 Research Assistant, School of Chinese Medicine, CUHK

Research Interests:

  1. Study on the molecular mechanism research (mainly involves in cell apoptosis, autophagy, metastasis, drug resistance, prevent tumor recurrence) and drug development of Chinese medicine and its active ingredients in the treatment of pancreatic cancer and breast cancer

Representative publications in reverse:

  1. Xian YF*, Zhang J*, Bian ZX, Zhou H, Zhang ZB, Lin ZX, Xu HX. Bioactive natural compounds against human coronaviruses: a review and perspective. Acta Pharm Sin B, (2020)10(7):1163-1174. (Co-first author)
  2. Han L, Xu DQ, Xi ZC, Wu M, Wan Najbah Nik Nabil, Zhang J, Xu HX, et al. The natural compound Oblongifolin C exhibits anticancer activity by inhibiting HSPA8 and Cathepsin B in vitro. Frontiers in pharmacology, (2020)11:564833
  3. Ye Y, Wu M, Lao YZ, Fu W, Yang X, Zhang J, Xu HX, Xu G. Dearomatized Isoprenylated Acylphloroglucinol Derivatives with Potential Antitumor Activities from Hypericum henryi. Nat Prod Bioprospect, (2020)10(1):1-11.
  4. Zhang J, Zheng Z, Wu M, Lao Y, Xu H, et al. The natural compound neobractatin inhibits tumor metastasis by upregulating RNA-binding-protein MBNL2, Cell Death & Disease, (2019)10:554.
  5. Zheng Z, Wu M, Zhang J, Fu W, Xu N, Lao YZ, Xu HX. The natural compound neobractatin induces cell cycle arrest by regulating E2F1 and GADD45α. Frontiers in oncology, (2019) 9: 654.
  6. Yuan M, Xu L, Zhang J, Kong S, Wu M, Lao YZ, Xu HX. SRC and MEK co-inhibition synergistically enhances the anti-tumor effect in both NSCLC and erlotinib resistant NSCLC cells. Frontiers in oncology, (2019) 9: 586.
  7. Duan Y*, Zhang J*, et al. Spirocyclic polycyclic polyprenylated acylphloroglucinols from the ethyl acetate fraction of Hypericum henryi, Tetrahedron Letters, 2018, 59 (2018): 4067–4072 (Co-first author)


Copyright © 2023 School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong. All Rights Reserved.